Plus therapeutics announces new employment inducement grants

Austin, texas, nov. 12, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that on november 11, 2021, it granted option awards to norman lafrance, m.d. consistent with the disclosures contained in the company's form 8-k filed with the u.s. securities and exchange commission on september 13, 2021, the company agreed to grant these equity awards on dr. lafrance's start date to induce dr. lafrance to commence employment as its chief medical officer.
PSTV Ratings Summary
PSTV Quant Ranking